Specific Phenotype Relevant in Subclinical Primary Aldosteronism

Share this content:
Specific Phenotype Relevant in Subclinical Primary Aldosteronism
Specific Phenotype Relevant in Subclinical Primary Aldosteronism

TUESDAY, Oct. 10, 2017 (HealthDay News) -- A suppressed renin phenotype is associated with higher incidence of incident hypertension than other plasma renin activity (PRA) phenotypes, according to a study published online Oct. 9 in the Annals of Internal Medicine.

Jennifer M. Brown, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a cohort study involving 850 untreated normotensive participants in the Multi-Ethnic Study of Atherosclerosis to examine whether a spectrum of subclinical renin-independent aldosteronism that increases the risk of hypertension exists.

The researchers found that compared with other PRA phenotypes, a suppressed renin phenotype correlated with a higher rate of incident hypertension (suppressed renin phenotype, 85.4 events; indeterminate renin phenotype, 53.3 events; unsuppressed renin phenotype, 54.5 events per 1,000 person-years of follow-up). There was an independent correlation between higher aldosterone concentrations and increased risk for incident hypertension with renin suppression; when renin was not suppressed there was no correlation between aldosterone and hypertension. When renin was suppressed there was a correlation for higher aldosterone concentrations with lower serum potassium and higher urinary excretion of potassium.

"These findings suggest a clinically relevant spectrum of subclinical primary aldosteronism (renin-independent aldosteronism) in normotension," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »